General
Preferred name
QUETIAPINE
Synonyms
QUETIAPINE FUMARATE ()
Quetiapine hemifumarate ()
Quetiapine (D4 fumarate) ()
Quetiapine (fumarate) ()
ICI204636 ()
Quetiapin ()
ICI-204636 ()
Seroquel ()
Quetiapine (hemifumarate) ()
ICI-204636 fumarate ()
Quetiapine (ICI-204636) fumarate ()
Quetiapine (hemifumarate) (CRM) ()
NSC-758918 ()
Quetiapine extended release ()
Sondate XL ()
Biquelle XL ()
Zaluron XL ()
Seotiapim XL ()
Norsic ()
Mintreleq XL ()
Tenprolide XL ()
Seroquel XL ()
Atrolak XL ()
Ebesque XL ()
Psyquet XL ()
Brancico XL ()
Quetiapina ()
Quetiapine (as fumarate) ()
ZD5077 ()
Seroquel Xr ()
ZM 204,636 ()
Utapine ()
FK947E ()
ICI 204,636 ()
ZM-204636 ()
ZD-5077 ()
FK-947E ()
Quetiapine-d8 (fumarate) ()
P&D ID
PD009953
CAS
111974-72-2
111974-69-7
1185247-12-4
Tags
available
drug
Approved by
FDA
First approval
1997
Drug indication
Schizophrenia
Alcohol dependence
Psychosis
Post-traumatic stress disorder
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
METABOLISM Hepatic. The major metabolic pathways are sulfoxidation, mediated by cytochrome P450 3A4 (CYP3A4), and oxidation of the terminal alcohol to a carboxylic acid. The major sulfoxide metabolite of quetiapine is inactive. Quetiapine also undergoes hydroxylation of the dibenzothiazepine ring, O-deakylation, N-dealkylation, and phase II conjugation. The 7-hydroxy and 7-hydroxy-; N-delakylated metabolites appear to be active, but are present in very low concentrations.
DESCRIPTION Quetiapine displays affinity for numerous receptors from the dopamine, serotonin and adrenergic families, in addition to the histamine H1 receptor. The anti-psychotic properties of the drug are believed to result from its antagonism of dopamine D2 and 5-HT2A receptors.
Marketed formulations may contain quetiapine fumarate (PubChem CID 5281025) or quetiapine hemifumarate (PubChem CID 73013330). (GtoPdb)
DESCRIPTION Quetiapine (ICI204636) is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1].
PRICE 41
DESCRIPTION Quetiapine (ICI204636) is used for the therapy of schizophrenia, and for the treatment of acute manic episodes associated with bipolar I disorder. The mechanism of quetiapine' action is thought by mediated through antagonist activity at serotonin and dopamine receptors. Specifically, the D1 and D2 dopamine, the ??1 adrenoreceptor and ??2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also can inhibit the histamine H1 receptor.
DESCRIPTION Quetiapine hemifumarate is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine hemifumarate is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1].
DESCRIPTION Potent and selective sphingosine-1-phosphate receptor 1 (S1P1) agonist (Tocris Bioactive Compound Library)
DESCRIPTION 5-HT2/D2 antagonist; atypical antipsychotic (Tocriscreen Plus)
DESCRIPTION Quetiapine hemifumarate is an atypical antipsychotic. It is used in the treatment of schizophrenia, bipolar mania, bipolar depression. It shows affinity for serotonin, dopamine, histamine, and adrenergic receptors. (Enamine Bioactive Compounds)
DESCRIPTION Quetiapine hemifumarate (ICI-204636), an atypical antipsychotic, is used in the treatment of bipolar I mania, schizophrenia, bipolar II depression, bipolar I depression. (TargetMol Bioactive Compound Library)
DESCRIPTION Quetiapine (ICI204636) is used for the therapy of schizophrenia, and for the treatment of acute manic episodes associated with bipolar I disorder. The mechanism of quetiapine' action is thought by mediated through antagonist activity at serotonin and dopamine receptors. Specifically, the D1 and D2 dopamine, the α1 adrenoreceptor and α2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also can inhibit the histamine H1 receptor. (TargetMol Bioactive Compound Library)
Compound Sets
38
AdooQ Bioactive Compound Library
A10767
Axon Medchem Screening Library
1354
Cayman Chemical Bioactives
14152
22603
23981
32946
ChEMBL Approved Drugs
CHEMBL3188993
CHEMBL716
ChEMBL Drugs
CHEMBL3188993
CHEMBL716
Concise Guide to Pharmacology 2019/20
50
Concise Guide to Pharmacology 2021/22
50
Concise Guide to Pharmacology 2023/24
50
Drug Repurposing Hub
DrugBank
DB01224
DrugBank Approved Drugs
DB01224
DrugCentral
2337
DrugCentral Approved Drugs
2337
DrugMAP
DM1N62C
DrugMAP Approved Drugs
DM1N62C
DrugMatrix
Enamine Bioactive Compounds
EBC-15049
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS102173
Guide to Pharmacology
50
Ki Database
Quetiapine
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL716
Mcule NIBR MoA Box Subset
MCULE-1498636422
MedChem Express Bioactive Compound Library
HY-14544
HY-B0031
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
BGL0JSY5SI
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Quetiapine-fumarate(Seroquel)
quetiapine
TargetMol Bioactive Compound Library
T6241
T0162
The Spectrum Collection
Tocris Bioactive Compound Library
4735
Tocriscreen Plus
4735
VGSC-DB
NA0058
External IDs
93
Properties
(calculated by RDKit )
Molecular Weight
383.17
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
2
cLogP
2.86
TPSA
48.3
Fraction CSP3
0.38
Chiral centers
0.0
Largest ring
7.0
QED
0.8
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
7-TM Receptors
Target
Dopamine Receptor
5-HT Receptor
Adrenergic Receptor
dopamine
HT
ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR3A, HTR6, HTR7, SLC6A2
Atypical antipsychotic
5-HT Receptor,Dopamine Receptor
5-HT
H1 receptor
mAChR
Pathway
GPCR/G protein
Neuronal Signaling
Immunology/Inflammation
Neuroscience
Primary Target
Non-selective 5-HT2
MOA
Antagonist
alpha1-Adrenoceptor Antagonists
dopamine receptor antagonist, serotonin receptor antagonist
Member status
virtual
Indication
schizophrenia, bipolar disorder
Therapeutic Indication
Neuroleptic
Therapeutic Class
CNS & PNS
Antipsychotic Agents
VGSC Target
Nav1.5
Source data